These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21879313)

  • 1. Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C.
    Aizawa Y; Yohizawa K; Aida Y; Ishiguro H; Abe H; Tsubota A
    Mol Cell Biochem; 2012 Jan; 360(1-2):9-14. PubMed ID: 21879313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
    Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Nakamura Y; Kumada H
    Hepatology; 2010 Aug; 52(2):421-9. PubMed ID: 20648473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.
    Toyoda H; Kumada T; Hayashi K; Honda T; Katano Y; Goto H; Kawaguchi T; Murakami Y; Matsuda F
    J Med Virol; 2011 Sep; 83(9):1559-64. PubMed ID: 21739446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.
    Maekawa S; Sakamoto M; Miura M; Kadokura M; Sueki R; Komase K; Shindo H; Komatsu N; Shindo K; Kanayama A; Ohmori T; Amemiya F; Takano S; Yamaguchi T; Nakayama Y; Kitamura T; Inoue T; Okada S; Enomoto N
    Hepatology; 2012 Nov; 56(5):1611-21. PubMed ID: 22577043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus.
    Hiraga N; Abe H; Imamura M; Tsuge M; Takahashi S; Hayes CN; Ochi H; Tateno C; Yoshizato K; Nakamura Y; Kamatani N; Chayama K
    Hepatology; 2011 Sep; 54(3):764-71. PubMed ID: 21618576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between genetic variations and serum level of interleukin 28B with virus genotypes and disease progression in chronic hepatitis C virus infection.
    Al-Qahtani A; Al-Anazi M; Abdo AA; Sanai FM; Al-Hamoudi W; Alswat KA; Al-Ashgar HI; Khan MQ; Albenmousa A; Khalaf N; Viswan N; Al-Ahdal MN
    J Immunol Res; 2015; 2015():768470. PubMed ID: 25811035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
    Hayes CN; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Imamura M; Ochi H; Kamatani N; Nakamura Y; Chayama K
    Gut; 2011 Feb; 60(2):261-7. PubMed ID: 21068134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Tada T; Kawaguchi T; Murakami Y; Matsuda F
    J Med Virol; 2011 Jul; 83(7):1203-11. PubMed ID: 21567424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.
    Clark PJ; Thompson AJ; Zhu M; Vock DM; Zhu Q; Ge D; Patel K; Harrison SA; Urban TJ; Naggie S; Fellay J; Tillmann HL; Shianna K; Noviello S; Pedicone LD; Esteban R; Kwo P; Sulkowski MS; Afdhal N; Albrecht JK; Goldstein DB; McHutchison JG; Muir AJ;
    J Viral Hepat; 2012 May; 19(5):332-40. PubMed ID: 22497812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
    Moghaddam A; Melum E; Reinton N; Ring-Larsen H; Verbaan H; Bjøro K; Dalgard O
    Hepatology; 2011 Mar; 53(3):746-54. PubMed ID: 21374656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.
    Li JH; Lao XQ; Tillmann HL; Rowell J; Patel K; Thompson A; Suchindran S; Muir AJ; Guyton JR; Gardner SD; McHutchison JG; McCarthy JJ
    Hepatology; 2010 Jun; 51(6):1904-11. PubMed ID: 20235331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Hara T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    Hepatology; 2012 Dec; 56(6):2134-41. PubMed ID: 22806754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Nakamura Y; Kumada H
    Intervirology; 2012; 55(6):417-25. PubMed ID: 21325786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.
    Kim SR; El-Shamy A; Imoto S; Kim KI; Ide YH; Deng L; Shoji I; Tanaka Y; Hasegawa Y; Ota M; Hotta H
    J Gastroenterol; 2012 Oct; 47(10):1143-51. PubMed ID: 22441534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.
    Kobayashi M; Suzuki F; Akuta N; Sezaki H; Suzuki Y; Hosaka T; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Miyakawa Y; Kumada H
    J Gastroenterol; 2012 May; 47(5):596-605. PubMed ID: 22438096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
    Kurosaki M; Tanaka Y; Nishida N; Sakamoto N; Enomoto N; Honda M; Sugiyama M; Matsuura K; Sugauchi F; Asahina Y; Nakagawa M; Watanabe M; Sakamoto M; Maekawa S; Sakai A; Kaneko S; Ito K; Masaki N; Tokunaga K; Izumi N; Mizokami M
    J Hepatol; 2011 Mar; 54(3):439-48. PubMed ID: 21129805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of Interleukin 28B rs12979860 and rs8099917 Polymorphisms and T-helper 1 Response in Hepatitis C Virus Patients.
    Ea R; Aa G; Ag ES; Ma A
    Egypt J Immunol; 2015 Jun; 22(2):57-68. PubMed ID: 28502145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.